M2型极化巨噬细胞与多发性骨髓瘤早期治疗反应的关系及其分子机制
该研究收集240例多发性骨髓瘤患者骨髓活检组织,以抗CD163单克隆抗体标记M2型极化巨噬细胞,并在体外将M2巨噬细胞与RPMI 8226和U266细胞共培养。结果发现骨髓M2巨噬细胞高浸润组早期治疗有效率低于低浸润组(23.9%对73.0%,P<0.001),M2巨噬细胞可促进骨髓瘤细胞增殖、抑制地塞米松诱导的凋亡并上调IL-6、TNF-α、CCL2、CCL3、CCR2、CCR5、VEGFA及VEGFR-1、VEGFR-2表达。
要点
- 骨髓M2巨噬细胞高浸润组早期治疗有效率23.9%,低于低浸润组的73.0%(P<0.001)。
- M2巨噬细胞降低地塞米松诱导的骨髓瘤细胞凋亡率并上调IL-6、TNF-α及趋化因子、VEGF相关表达。
核心结论
- 多发性骨髓瘤患者骨髓组织M2巨噬细胞浸润程度与早期治疗反应相关。
- M2巨噬细胞通过促进骨髓瘤细胞分泌炎症因子、趋化因子及相关受体表达,促进骨髓瘤细胞增殖并保护其免于凋亡。
研究设计与样本
- 收集240例多发性骨髓瘤患者骨髓活检组织,采用抗CD163单克隆抗体免疫组化法标记M2型极化巨噬细胞。
- 体外由人外周血单个核细胞或THP-1细胞诱导M2型极化巨噬细胞并经流式细胞术鉴定。
- 以Transwell系统将RPMI 8226和U266骨髓瘤细胞与M2巨噬细胞共培养,CCK-8法检测增殖,ELISA检测TNF-α和IL-6,real time PCR检测趋化因子及VEGF相关表达,流式细胞术检测地塞米松(1 μmol/L)诱导的凋亡。
主要发现
- 依据骨髓M2巨噬细胞浸润程度分为高浸润组(92例)和低浸润组(148例),高浸润组早期治疗有效率23.9%,低于低浸润组的73.0%(χ²=60.31,P<0.001)。
- 培养24、36小时,M2巨噬细胞共培养的RPMI 8226细胞增殖高于对照组(24小时P=0.005,36小时P=0.020),U266细胞亦高于对照组(24小时P=0.030,36小时P=0.020)。
- 地塞米松诱导后,共培养组RPMI 8226细胞凋亡率为29.0%,低于对照组的71.0%(t=4.97,P=0.008);U266细胞凋亡率为24.9%,低于对照组的67.7%(t=6.99,P=0.002)。
- 共培养48小时后,加入M2巨噬细胞可促进RPMI 8226和U266细胞分泌IL-6、TNF-α,并促进CCL2、CCL3、CCR2、CCR5、VEGFA、VEGFR-1和VEGFR-2表达,均高于无巨噬细胞共培养体系。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the relationship between M2-polarized macrophages and early response in multiple myeloma and its molecular mechanism. Methods: Two hundred and forty bone marrow biopsy tissue were collected and M2-polarized macrophages were stained by anti-CD163 monoclonal antibody. In vitro M2-polarized macrophages were derived from human peripheral blood mononuclear cell or THP-1 cells and identified by flow cytometry. Two myeloma cell lines RPMI 8226 and U266 were co-cultured with M2 macrophages using a transwell system. We measured myeloma cells proliferation through CCK-8 method and the pro-inflammatory cytokines expression (TNF-α and IL-6) by ELISA. Real time PCR was applied to measure chemokines (CCL2 and CCL3) , chemokine receptors (CCR2, CCR5) , VEGF and their receptors. In addition, flow cytometry was used to analyze the apoptosis of myeloma cells induced by dexamethasone. Results: ①Patients with high percentage of M2 macrophage involvement in bone marrow showed poorer response (23.9% versus 73.0%, χ(2)=60.31, P<0.001). ② In vitro the proliferation of RPMI 8226 cells (P=0.005 at 24 h, P=0.020 at 36 h) or U266 myeloma cells (P= 0.030 at 24h, P=0.020 at 36h) co-cultured with M2-polarized macrophages was higher than control group. ③In vitro the apoptotic rate of RPMI 8226 cells (29.0% versus 71.0%, t=4.97, P=0.008) or U266 myeloma cells (24.9% versus 67.7%, t=6.99, P=0.002) co-cultured with M2-polarized macrophages was lower than control group. ④ In vitro M2-polarized macrophages promoted myeloma cells secreting higher level of IL-6, TNF-α and higher expression of CCL2, CCL3, CCR2, CCR5, VEGFA, VEGFR-1,-2 compared with the non-macrophage co-culture system. Conclusion: M2-polarized macrophages promote myeloma cells proliferation and inhibit apoptosis through a very complex mechanism involving pro-inflammatory cytokines IL-6 and TNF-α, chemokines and related receptors such as CCL2, CCL3, CCR2, CCR3, and VEGF as well as related VEGFR. 目的: 探讨替代活化型巨噬细胞(M2 MΦ)和多发性骨髓瘤(MM)早期治疗反应的关系及其在发病机制中的可能作用。 方法: 采用免疫组化法标记240例MM患者骨髓标本中的MΦ;建立体外M2 MΦ诱导培养体系,构建Transwell共培养模型与RPMI 8226和U266细胞共培养,CCK-8法检测M2 MΦ对细胞增殖的影响,流式细胞术检测对地塞米松(1 μ mol/L)诱导骨髓瘤细胞凋亡的影响,ELISA法检测对TNF-α和IL-6表达的影响,real time PCR法检测对趋化因子、血管内皮生长因子(VEGF)及其受体表达的影响。 结果: ①依据骨髓组织M2 MΦ浸润程度将患者分为高浸润组(92例)和低浸润组(148例),高浸润组患者早期治疗有效率明显低于低浸润组,差异有统计学意义(23.9%对73.0%,χ(2)=60.31,P<0.001)。②培养24、36 h,共培养组细胞增殖能力较对照组显著上升:M2 MΦ+RPMI 8226细胞组与对照组比较,P值分别为0.005、0.020;M2 MΦ+U266细胞与对照组比较,P值分别为0.030、0.020。③地塞米松诱导后,共培养组与对照组比较,RPMI 8226细胞凋亡率下降(29.0%对71.0%,t=4.97,P=0.008),U266细胞凋亡率也下降(24.9%对67.7%,t=6.99,P=0.002)。④共培养48 h后,与对照组比较,加入M2 MΦ后可促进RPMI 8226和U266细胞分泌IL-6、TNF-α,促进表达CCL2、CCL3、CCR2、CCR5、VEGFA、VEGFR-1和VEGFR-2。 结论: MM患者骨髓组织M2 MΦ浸润程度和早期治疗反应相关。M2 MΦ通过促进骨髓瘤细胞分泌系列炎症因子、趋化因子和相关受体的表达,从而促进骨髓瘤细胞增殖以及保护骨髓瘤细胞免于凋亡。.
引用
- Chen XY, Sun RX, Zhang WY, et al. [Molecular mechanisms and relationship of M2-polarized macrophages with early response in multiple myeloma]. Zhonghua Xue Ye Xue Za Zhi. 2017. PMID: 28655090. doi:10.3760/cma.j.issn.0253-2727.2017.06.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。